LeonaBio

LONAPhase 3

LeonaBio is dedicated to developing novel therapeutics for devastating diseases with limited treatment options, focusing on oncology and neurology. The company's strategy leverages two distinct, late-stage small molecule candidates: lasofoxifene for treatment-resistant metastatic breast cancer and ATH-1105 for ALS. Following a significant financing and licensing deal for lasofoxifene in late 2025, LeonaBio is advancing its Phase 3 ELAINE-3 trial while building a pipeline of earlier-stage compounds. The company is led by an experienced management team with deep expertise in biotech development and finance.

Market Cap

$45.7M

Focus

Small Molecules

LONA · Stock Price

USD 4.90166.20 (-97.14%)

Historical price data

AI Company Overview

Technology Platform

The company leverages distinct small molecule mechanisms: targeting mutant estrogen receptors (ESR1) in oncology and positively modulating the neurotrophic hepatocyte growth factor (HGF) system in neurology.

Pipeline Snapshot

8 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
ATH-1017	Alzheimer Disease	Phase 2/3
ATH-1017 + Placebo	Alzheimer Disease	Phase 2/3
ATH-1017 + Placebo	Alzheimer Disease	Phase 2
ATH-1017 + Placebo	Parkinson Disease Dementia	Phase 2
ATH-1020 + Placebo	Healthy Volunteers	Phase 1

Opportunities

The primary growth opportunity is the successful development and commercialization of lasofoxifene for the genomically-defined ESR1-mutated metastatic breast cancer population, a market with high unmet need.

A secondary opportunity lies in advancing ATH-1105 as a novel, oral neuroprotective therapy for ALS, another area with limited treatment options.

Risk Factors

Key risks include clinical trial failure of the lead asset lasofoxifene in Phase 3, intense competition in the metastatic breast cancer space, high dependence on a single late-stage program, and the challenge of efficiently deploying the recent $236 million financing to achieve pivotal milestones.

Competitive Landscape

In metastatic breast cancer, lasofoxifene competes with approved SERDs like elacestrant and other late-stage therapies; its differentiation is based on its specific mutant-ESR1 activity and combination strategy. In ALS, ATH-1105's unique mechanism as an oral HGF positive modulator distinguishes it from other neuroprotective approaches and recently approved drugs.